Ultragenyx Pharmaceutical granted 22,917 restricted stock units to six new non-executive officers as employment inducement.
Quiver AI Summary
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on developing therapies for rare diseases, announced the granting of 22,917 restricted stock units to six newly hired non-executive officers. This award, approved by the company's compensation committee, is part of the Ultragenyx Employment Inducement Plan and aims to incentivize the new employees as they begin their roles. The restricted stock units will vest over four years, with 25% vesting each year, contingent on the employees' continuous employment. Ultragenyx is dedicated to delivering innovative treatments for serious genetic diseases that currently lack approved therapies, leveraging its experienced management team and efficient drug development strategies. For more information, stakeholders can visit the Ultragenyx website.
Potential Positives
- The grant of 22,917 restricted stock units to six newly hired non-executive officers demonstrates the company's commitment to attracting and retaining talent in its leadership team.
- This move aligns with the company's strategy to enhance its development and commercialization capabilities for rare and ultrarare diseases, potentially leading to more efficient drug development.
- The awards were approved under the Ultragenyx Employment Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4), indicating corporate governance adherence and a structured approach to employee incentives.
- The vesting schedule of the restricted stock units, which spans four years, promotes long-term employee retention and aligns the interests of new hires with the company's growth and success.
Potential Negatives
- The issuance of restricted stock units to newly hired non-executive officers may raise concerns about potential dilution of existing shareholder value.
- This significant compensation could be viewed as a signal that the company is making strategic changes or facing challenges in attracting top talent.
- The reliance on restricted stock units as an inducement could imply difficulties in recruitment or retention in a competitive industry landscape.
FAQ
What is the recent stock award announcement by Ultragenyx?
Ultragenyx announced the grant of 22,917 restricted stock units to six newly hired non-executive officers as an employment inducement.
Who approved the stock units grant at Ultragenyx?
The compensation committee of Ultragenyx's board of directors approved the grant of restricted stock units.
What is the vesting schedule for the stock units?
The restricted stock units vest over four years, with 25% vesting on each anniversary of the grant date.
What is the purpose of the Ultragenyx Employment Inducement Plan?
The plan aims to provide inducement material to new employees entering into employment with Ultragenyx as per Nasdaq rules.
How does Ultragenyx address rare diseases?
Ultragenyx focuses on developing therapies for rare and ultra-rare genetic diseases, aiming to meet high unmet medical needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RARE Insider Trading Activity
$RARE insiders have traded $RARE stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $RARE stock by insiders over the last 6 months:
- HOWARD HORN (Chief Financial Officer) has made 0 purchases and 3 sales selling 14,084 shares for an estimated $434,456.
- KARAH HERDMAN PARSCHAUER (EVP and Chief Legal Officer) sold 2,450 shares for an estimated $76,366
- THEODORE ALAN HUIZENGA (SVP, Chief Accounting Officer) has made 0 purchases and 3 sales selling 233 shares for an estimated $7,425.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RARE Hedge Fund Activity
We have seen 163 institutional investors add shares of $RARE stock to their portfolio, and 202 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 4,617,047 shares (-63.4%) from their portfolio in Q4 2025, for an estimated $106,192,081
- CITADEL ADVISORS LLC added 1,995,172 shares (+602.9%) to their portfolio in Q4 2025, for an estimated $45,888,956
- ALKEON CAPITAL MANAGEMENT LLC removed 1,685,729 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $50,706,728
- DEEP TRACK CAPITAL, LP removed 1,350,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $40,608,000
- RTW INVESTMENTS, LP added 1,292,737 shares (+75.7%) to their portfolio in Q4 2025, for an estimated $29,732,951
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,099,474 shares (-71.9%) from their portfolio in Q3 2025, for an estimated $33,072,177
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 983,715 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $22,625,445
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RARE Analyst Ratings
Wall Street analysts have issued reports on $RARE in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 12/30/2025
- Baird issued a "Outperform" rating on 12/30/2025
- Barclays issued a "Overweight" rating on 11/24/2025
- TD Cowen issued a "Buy" rating on 11/05/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/09/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/05/2025
To track analyst ratings and price targets for $RARE, check out Quiver Quantitative's $RARE forecast page.
$RARE Price Targets
Multiple analysts have issued price targets for $RARE recently. We have seen 14 analysts offer price targets for $RARE in the last 6 months, with a median target of $55.0.
Here are some recent targets:
- Liisa Bayko from Evercore ISI Group set a target price of $34.0 on 02/18/2026
- Whitney Ijem from Canaccord Genuity set a target price of $79.0 on 02/18/2026
- Laura Chico from Wedbush set a target price of $25.0 on 02/17/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $50.0 on 02/17/2026
- Debjit Chattopadhyay from Guggenheim set a target price of $52.0 on 01/05/2026
- Tazeen Ahmad from B of A Securities set a target price of $58.0 on 01/02/2026
- Joel Beatty from Baird set a target price of $47.0 on 12/30/2025
Full Release
NOVATO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 22,917 restricted stock units of the company’s common stock to six newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of February 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
